

# Fidson Healthcare Plc.

**Corporate Profile** 








## **About us**



- Fidson Healthcare Plc, an indigenous company was incorporated in 1995 as Fidson Drugs Limited to carry out the business of importation, marketing and distribution of pharmaceutical products
- The company first forayed into pharmaceutical manufacturing in
   2002 after commissioning our first manufacturing plant
- Fidson was listed on the Nigerian Stock Exchange NSE in
   2008 and became Fidson Healthcare Plc
- Our head office is in the heart of Lagos while our WHO compliant manufacturing facility is in Sango Ota, Ogun State, Nigeria
- The factory occupies a **site of approximately 40 acres** consisting of the different buildings


## Who we are

Fidson Healthcare Plc. is engaged in the business of manufacturing, marketing and sales of quality pharmaceutical and healthcare products. We are a wholly Nigerian enterprise that has grown to become a leader in the Nigerian pharmaceutical sector.



## **OUR MISSION**

To be the preferred company that adds value to life with brands that deliver sustainable, profitable growth.



## **OUR VISION**

To be the preferred healthcare provider.

## **Core values**













## **Innovation**

Our creativity, resourcefulness and penchant for problem solving, is uncompromised

## **Excellence**

Our unreserved consistency in quality of delivery and high performance ensures that we exceed expectations

## **Passion**

Our dedication and enterprising propensity drives us to deliver exceptional results in everything we do

## **Ownership**

We display initiative, exercising possession and control of activities and tasks with a positive attitude

## Integrity

Trustworthiness and upholding ethics and professionalism are some of our hallmarks

## **Our History**

### Milestones



#### 1995 Incorporation and commenced operations as a local drug distributor

## 2005 No1 1st Local

## manufacturer of ARVs in Nigeria

## 2007 & 2008

NIS ISO 9001:2000 Certification

<sup>a</sup>Raised N3 5b via Private Placement

Listed on the **NSE in 2008** 

#### 2014

Nigerian Healthcare **Excellence Awards** BusinessDay Top 25 CEO Awards -

Raised N2bn via a publicly guoted Bond Issue

2013 & 2014

2014

Growth,

Innovation

**Excellence** 

**BusinessDav** 

Top 25 CEO

**Awards** - 2015

**Awards** 

2014

Frost & Sullivan

#### 2016

**WHO Compliant** Manufacturing Facility Commissioned

#### 2019+

FMS ISO 14001:2015 Certification

Raised N2.3b via Rights Issue

Appointed by GSK as local manufacturing partner

Strategic partnership with Ohara, Japan





1	9	9	5	

2002

1st Factory

and became

PPI in Nigeria

the 1st

commissioned

Manufacturer of

#### 2002 2005

## 2006

2006

Nigeria

Completed 2<sup>nd</sup>

manufacturing

plant in Ota,

## 2007

2011& 2012

2008 certified

Nigerian Stock

the Year

Exchange CEO of

Became ISO 9001:

#### 2011

#### 2014 2015

### 2016

## 2018

2018

Frost & Sullivan

**Pharmaceutical** 

Strategy Award

Production

Competitive

2018

## 2019

## 2020

## **Product** Innovation

## **Exports**

## Expansion

# Manufacturing

### **Exports**

### 2021

2020

#### Commenced Contract Mfg. for GSK

Signed Contract partnership with Baver AG

### NECA's Best **Employer** Pharmaceutical

2022

2021

& HMO **IAS Pharma** Manufacturing Excellence **Awards** 

**Best Performing** Stock in the Healthcare sector (NGX)

2023

2022 2023 & 2024

agreement with Serum Institute of India for Malaria vaccine

Signed

### No<sub>1</sub>

Pioneered ampoule injection manufacturing in Nigeria Pharma Industry

## No1 First in Nigeria Pharma Industry

## **Acknowledgements**







2021-2024 (4x)



Great Place To Work





2025

Pharmaceutical Best Employer in Pharmaceutical Company of the Year Best Employer in Pharmaceutical & HMO Sector Category

2022

Winner Health Sector Best Performance Initiative

2nd Runner up – HR Best Practices Awards 2020

Certification as Great Place to Work 2019-2020

Award for Best Workplaces (Large Corporate Organizations)

Winner of Best Quality of Life Award (Large Corporate organization) 2018

Best Employee Engagement Program 2018

Winner of the Frost & Sullivan – Best Practice Award for Competitive Strategy Innovation and Leadership.

# **Our Key Strengths**



**People** 

**Products** 

**Process** 

TOTAL

TOTAL

TOTAL

1800+

350+

10

**Employees** 

**NAFDAC Registered Brands** 

**Production Lines** 

206 Professionals largest employer of pharmacists outside state & federal government

Local Manufacturing POMs & OTC Nutraceutical Herbals

Largest manufacturing facility in Nigeria and arguably West Africa

## **Our Certifications**





We currently run a globally-accepted cGMP compliant manufacturing facility.

Fidson Healthcare Plc.



We are **1 of 5** Nigerian pharmaceutical manufacturers that are candidates for the WHO GMP certification.



We maintain an Environmental Management System - EMS in compliance with ISO 14001-2015 standard that minimizes the impact of our operations on the environment.

# **Our People**

Fidson has maintained a stable management team with **over 300 years of combined experience**, and seasoned directors.



Dr. Babatunde Ipaye, MPH, FWACP Non-Executive Director



Philip Ejiofor, FCA Non-Executive Director



Dr. Vincent Ahonkai, FAAP Non-Executive Director

Fidelis Ayebae

Founder/Chairman



Emmanuel E. Imoagene Non-Executive Director



Olugbenga Olayeye Strategy Director



Ola Eboh Ijimakin Commercial Director



Imokha Ayebae Finance Director



Oshoke Ayebae
Business Development
Director



Gbenga Olayemi Associate Director, Commercial



**Adejoke Alli** GM, Business Operations



Raphael Ajayi GM, Supply Chain



**Nmaka Tijani** GM, Quality and Regulatory Affairs




Abibatu Ariori Head of Factory Operations

## Revenue Performance



Revenue Trend 2014 - 2024



## Key Highlights - FY 2024 vs 2023

Metric	FY 2024 Value	YoY Growth
Revenue	₦84.2 billion	+59.0%
Cost of Sales	₦49.0 billion	+53.1%
Gross Profit	₦35.1 billion	+67.1%
Selling & Distribution Expenses	₦8.1 billion	+47.3%
Operating Profit	₩13.1 billion	+63.7%
Profit Before Tax	₦7.7 billion	+30.5%
Profit for the Year	₦5.8 billion	+3.6%
Total Assets	₦73.5 billion	+18.5%

In 2024, Fidson recorded N84.2 billion in revenue, representing a 59% increase from the N53.1 billion in revenue posted in 2023.

About 66.4% of revenue came from the sale of ethical products.

## **Products**

- Fidson is an innovative leader in the manufacturing segment of the Nigerian healthcare industry.
  - Over **350** different products and formulations across various therapeutic classes and pharmacological segments.
- Some major achievements:
  - **First** manufacturer of **ampoule injection** in the Nigerian pharmaceutical industry
  - Pioneering the manufacture of Proton Pump Inhibitors (PPI) utilized for the treatment and management of gastric ulcer conditions
  - Becoming the first company in West Africa to manufacture Anti-retroviral (ARVs) drugs.



**Antibiotics** 



**Haemanitics** 



Osteo-care



Cardiovascular



Anti-Malaria



**Neuro-psychiatry** 



Herbal & **Nutraceutical** 



**Analgesics** 



**Parenteral** 



**Anti-Diabetic** 



ARV



Gastrointestinal



**Capsules 1,900** million units pa. Based on **360mg** capsules





**Tablet**2,500 million units pa.
Based on 540mg tablets





**Syrup** 78 million units pa. Based on **100ml** bottles









**Cream**75 million units pa.
Based on 20mg tubes





Eye drop 65 million units pa.





Dialysis solution
25 million units

# **Facility Layout**



Block

Oral liquid - Two
(2) manufacturing
& packing lines

Block

Four (4)
manufacturing
lines
Cream &
Ointment, Tablet,
Capsule, and Dry
Powder

Block

Sterile Products -LVP & SVP preparations including eye drops, ampoule injection manufacturing and packing Block

Finished goods
warehouse
Quality department
- Instrumentation
room, Microbiology
room & Stability
Chambers

Block

Raw & packaging material warehouse

The building complex is divided into five (5) blocks - A,B,C,D & E in addition to the Administrative, Warehouse, External Production Line and Utility areas.

44

This is an impressive outfit from the variety of products, the amount of equipment, and the apparent commitment of the staff. Keep up the good work. It is noted and I am sure will be handsomely and adequately rewarded. Very pleased and happy to be here.









- 6

What Fidson has built here is extraordinary. We must encourage and support this project in terms of patronage and tax relief in order to ensure that the company is able to coordinate production in a sustainable manner

> Prof. Isaac Adewole Minister of Health (July, 2016)



"

Indigenous companies like Fidson Pharmaceuticals, which despite the economic downtum continue to expand its production capacity and base should be encouraged not only with local patronage but with favourable government policies and waivers that will spur them into doing more...

> Dr. Okechukwu Enelama Minister and Investment (July, 2017)









## **Contract Manufacturing**

In recent times, Fidson has made some strategic alliances with international brands like GlaxoSmithKline Consumer Nigeria Plc (GSK), Bayer AG. These strategic alliances have helped build local expertise through transfer of technical knowledge and improve local production capabilities for Fidson. In July 2019, Fidson entered a strategic alliance with Ohara, a leading Japanese pharmaceutical company. This strategic alliance with Ohara strengthens our position as a leader in the Nigerian pharmaceutical industry.



In April 2019, GSK announced the selection of Fidson as its local contract manufacturing partner. The strategic alliance makes Fidson the sole manufacturer of consumer products for GSK across West Africa

The selection of Fidson by GSK further attests the credibility and efficiency of Fidson as a leader in the Nigerian pharmaceutical industry



We have consummated a local manufacturing partnership with Bayer AG for production of their key products in Nigeria Other Contract Manufacturing Partnerships:

Kedi Healthcare Ltd.
Olpharm Pharmaceuticals
SkinScience

## **Our Reach**

With great emphasis on marketing, we depend on a network of highly skilled professional salespersons located across Nigeria

**150** 


Medical & Sales Representatives

Northern Region I
Northern Region II

**■** Eastern Region

Western Region

■ Lagos Region



# **Environmentally Responsible Business Practices**





Fidson utilizes natural gas, which reduces negative effects of emissions on the environment in accordance with UN sustainable development goals on environment.

Zero emissions from use of gas generators.



We practice waste separation at all sites, and work with the appropriate partners, like government and other certified agencies to ensure waste is processed and disposed properly.



DRIP is an organization wide initiative that seeks to systematically eliminate the use of paper in our operations.

All wastepaper generated in our operations is processed and disposed in accordance with EMS quidelines.



All wastewater from our manufacturing operations is treated to be reused in non-production related activities or disposed safely to the environment free of microbial and chemical contamination.

Wastewater treatment reduces demand for fresh water and protects the environment.

**Our Competitive Edge** 

## **Equitable Access**

High quality essential medicines at affordable prices

## **Quality Standards**

World Health Organization WHO compliant manufacturing facility

## **Supply Chain & Distribution**

Efficient supply chain system & network with capacity to deliver to any location in Nigeria
Africa Resource Centre for Excellence in Supply Chain (ARC\_ESM) scores Fidson a maximum 10 out of 10.

May 2024.

## **Tested & Trusted**

Proven track record with **State & Federal Government** 



## **Global Presence**





Exports - Africa & the middle East

**Institutions & Governments**